A translational study for phenotyping and endotyping Chinese patients with NCFBE

Trial Identifier: D9186R00001
Sponsor: AstraZeneca
Start Date: October 2025
Primary Completion Date: July 2027
Study Completion Date: July 2027
Condition: Lungs & Respiratory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China, Beijing Beijing, China
China, Chongqing Chongqing, China
China, Fujian Quanzhou, Fujian, China
China, Gansu Lanzhou, Gansu, China
China, Guangdong Shenzhen, Guangdong, China
China, Guangdong Zhanjiang, Guangdong, China
China, Guangxi Nanning, Guangxi, China
China, Guizhou Guiyang, Guizhou, China
China, Henan Zhengzhou, Henan, China
China, Hubei Shiya, Hubei, China
China, Hunan Changsha, Hunan, China
China, Jiangsu Xuzhou, Jiangsu, China
China, Jiangxi Nanchang, Jiangxi, China
China, Jilin Changchun, Jilin, China
China, Shandong Weifang, Shandong, China
China, Shanghai Shanghai, China
China, Sichuan Chengdu, Sichuan, China
China, Yunnan Anning, Yunnan, China
China, Yunnan Kunming, Yunnan, China
China, Zhejiang Hangzhou, Zhejiang, China
China, Zhejiang Jiaxing, Zhejiang, China
China, Zhejiang Ningbo, Zhejiang, China
China, Zhejiang Wenzhou, Zhejiang, China
China, Zhejing Huzhou, Zhejing, China
China, Zhejing Jiaxing, Zhejing, China
China, Zhengzhou Xinxiang, Zhengzhou, China